Skip to main content

Advertisement

Table 1 Patient characteristics at baseline (week 52, the start of HOPEFUL-2) in the effectiveness analysis set (n = 135)a

From: Low disease activity for up to 3 years after adalimumab discontinuation in patients with early rheumatoid arthritis: 2-year results of the HOPEFUL-3 Study

  ADA continuation group (n = 61) ADA discontinuation group (n = 74) p Valueb ADA continuation group p Valueb ADA discontinuation group p Valueb
Intensive therapy (ADA + MTX) (n = 28) Standard therapy (MTX alone) (n = 33) Intensive therapy (ADA + MTX) (n = 37) Standard therapy (MTX alone) (n = 37)
Female sex, n (%) 52 (85.2) 61 (82.4) 0.82 25 (89.3) 27 (81.8) 0.49 33 (89.2) 28 (75.7) 0.22
Age, years 58.3 ± 13.6 54.5 ± 12.4 0.06 59.5 ± 12.5 57.3 ± 14.5 0.58 53.4 ± 11.2 55.5 ± 13.6 0.41
Disease duration, years 1.3 ± 0.4 1.2 ± 0.3 0.35 1.3 ± 0.3 1.3 ± 0.5 0.46 1.2 ± 0.3 1.3 ± 0.3 0.20
MTX dose, mg/week 6.9 ± 1.8 7.1 ± 1.9 0.51 6.5 ± 1.4 7.3 ± 2.0 0.03c 7.0 ± 2.0 7.3 ± 1.8 0.19
Steroid use, n (%) 17 (27.9) 17 (23.0) 0.55 7 (25.0) 10 (30.3) 0.78 5 (13.5) 12 (32.4) 0.10
TJC28 score 0.7 ± 1.1 1.0 ± 2.0 0.93 0.4 ± 0.7 0.9 ± 1.3 0.08 1.3 ± 2.4 0.8 ± 1.4 0.39
SJC28 score 1.0 ± 1.7 0.4 ± 0.9 0.006d 1.1 ± 1.6 1.0 ± 1.9 0.24 0.5 ± 1.0 0.3 ± 0.8 0.57
CRP, mg/dl 0.2 ± 0.3 0.1 ± 0.2 0.93 0.2 ± 0.2 0.2 ± 0.3 0.10 0.1 ± 0.1 0.1 ± 0.2 0.33
ESR, mm/h 18.8 ± 14.2 18.3 ± 13.0 0.88 18.0 ± 13.1 19.5 ± 15.3 0.90 19.4 ± 12.5 17.2 ± 13.5 0.23
EGA score (VAS, mm) 8.2 ± 8.8 7.6 ± 7.1 0.81 8.8 ± 9.5 7.7 ± 8.3 0.73 8.1 ± 7.5 7.1 ± 6.7 0.73
PGA score (VAS, mm) 9.0 ± 9.0 8.5 ± 11.0 0.27 6.8 ± 7.1 10.8 ± 10.1 0.08 7.7 ± 8.9 9.2 ± 12.9 0.46
Pain score (VAS, mm) 8.2 ± 7.5 8.5 ± 10.5 0.56 6.8 ± 7.3 9.4 ± 7.6 0.13 7.6 ± 7.6 9.4 ± 12.7 0.51
DAS28-ESR 2.5 ± 0.8 2.4 ± 0.8 0.42 2.4 ± 0.6 2.6 ± 0.8 0.28 2.5 ± 0.8 2.2 ± 0.8 0.08
DAS28-CRP 1.8 ± 0.5 1.7 ± 0.6 0.23 1.8 ± 0.5 1.9 ± 0.5 0.35 1.8 ± 0.6 1.7 ± 0.6 0.52
HAQ-DI score 0.193 ± 0.273 0.199 ± 0.303 0.68 0.125 ± 0.167 0.250 ± 0.329 0.20 0.213 ± 0.296 0.186 ± 0.313 0.57
Erosion score 6.0 ± 7.7 7.1 ± 9.7 0.08 4.3 ± 4.8 7.3 ± 9.3 0.12 6.7 ± 12.3 7.5 ± 6.1 0.09
JSN score 3.4 ± 3.6 6.7 ± 13.1 0.31 2.2 ± 1.8 4.5 ± 4.4 0.04c 5.4 ± 15.1 8.1 ± 10.8 0.01c
mTSS 9.4 ± 10.4 13.9 ± 21.9 0.09 6.5 ± 5.9 11.8 ± 12.6 0.04c 12.1 ± 27.2 15.6 ± 15.0 0.02c
MMP-3 (ng/ml) 55.2 ± 44.1 60.7 ± 48.1 0.63 52.7 ± 31.9 57.4 ± 52.6 0.80 65.5 ± 49.9 56.0 ± 46.5 0.21
RF (U/ml) 62.8 ± 90.8 42.6 ± 51.8 0.85 50.6 ± 94.1 73.1 ± 88.1 0.11 41.8 ± 35.3 43.4 ± 64.8 0.26
ACPA (U/ml) 169.3 ± 257.8 216.2 ± 654.8 0.41 116.0 ± 255.0 214.6 ± 255.1 0.02c 167.6 ± 285.4 264.8 ± 885.0 0.10
  1. Abbreviations: ACPA Anti-cyclic citrullinated peptide antibody, ADA adalimumab, CRP C-reactive protein, DAS28-CRP 28-joint Disease Activity Score based on C-reactive protein, DAS28-ESR 28-joint Disease Activity Score based on erythrocyte sedimentation rate, EGA Evaluator global assessment, ESR Erythrocyte sedimentation rate, HAQ-DI Health Assessment Questionnaire Disability Index, JSN Joint space narrowing, MMP-3 Matrix metalloproteinase 3, mTSS Modified total Sharp score, MTX Methotrexate, PGA Patient global assessment, RF Rheumatoid factor
  2. a Values are expressed as mean ± SD, unless otherwise indicated
  3. b Statistical significance assessed by the Wilcoxon rank sum test
  4. c p < 0.05 ADA continuation group versus ADA discontinuation group, or initial intensive therapy (ADA + MTX) group versus standard therapy (MTX alone) group
  5. d p < 0.01 ADA continuation group versus ADA discontinuation group, or initial intensive therapy (ADA + MTX) group versus standard therapy (MTX alone) group